NYSE:IKT Inhibikase Therapeutics (IKT) Stock Price, News & Analysis $1.21 +0.05 (+4.31%) (As of 10:57 AM ET) Add Compare Share Share Today's Range$1.20▼$1.2150-Day Range$1.15▼$1.9952-Week Range$0.79▼$3.82Volume1,426 shsAverage Volume95,903 shsMarket Capitalization$8.74 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Inhibikase Therapeutics alerts: Email Address Inhibikase Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,882.8% Upside$23.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.87) to ($1.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.10 out of 5 stars 3.5 Analyst's Opinion Consensus RatingInhibikase Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageInhibikase Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Inhibikase Therapeutics' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IKT. Previous Next 0.0 Dividend Strength Dividend YieldInhibikase Therapeutics does not currently pay a dividend.Dividend GrowthInhibikase Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKT. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Inhibikase Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for IKT on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders14.70% of the stock of Inhibikase Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.81% of the stock of Inhibikase Therapeutics is held by institutions.Read more about Inhibikase Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($1.87) to ($1.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Inhibikase Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Inhibikase Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInhibikase Therapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Inhibikase Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Financial Markets DailyNYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech companyClick here for the company ticker About Inhibikase Therapeutics Stock (NYSE:IKT)Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.Read More IKT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IKT Stock News HeadlinesJuly 5 at 2:02 AM | americanbankingnews.comInhibikase Therapeutics (NYSE:IKT) Trading Down 4.9%June 17, 2024 | globenewswire.comInhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's DiseaseJuly 8, 2024 | Financial Markets Daily (Ad)NYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech companyJune 5, 2024 | globenewswire.comInhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development ProgramsMay 21, 2024 | finance.yahoo.comInhibikase Therapeutics First Quarter 2024 Earnings: US$0.73 loss per share (vs US$0.98 loss in 1Q 2023)May 20, 2024 | globenewswire.comInhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 MillionMay 19, 2024 | msn.comInhibikase Therapeutics, Inc. (NASDAQ:IKT) Q1 2024 Earnings Call TranscriptMay 18, 2024 | investing.comEarnings call: Inhibikase Therapeutics reports on drug trials progressJuly 8, 2024 | Financial Markets Daily (Ad)NYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be highly valuable for preparedness against novel viral epidemics and pandemics all while building shareholder value for this growing biotech companyMay 16, 2024 | msn.comIKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q1 2024May 15, 2024 | globenewswire.comInhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period ActivityMay 15, 2024 | globenewswire.comInhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration StatementMay 9, 2024 | globenewswire.comInhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial HypertensionApril 22, 2024 | msn.comLexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics among healthcare moversApril 20, 2024 | investing.comInhibikase Therapeutics progresses in Parkinson's disease trialsApril 18, 2024 | globenewswire.comInhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development ProgramsApril 3, 2024 | markets.businessinsider.comInhibikase Announces Pre-IND Meeting For IkT-001Pro - Quick FactsApril 3, 2024 | globenewswire.comInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial HypertensionSee More Headlines Receive IKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/08/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:IKT CUSIPN/A CIK1750149 Webwww.inhibikase.com Phone678-392-3419FaxN/AEmployees8Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$23.00 Low Stock Price Target$23.00 Potential Upside/Downside+1,882.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,030,000.00 Net MarginsN/A Pretax Margin-9,796.43% Return on Equity-147.03% Return on Assets-116.72% Debt Debt-to-Equity RatioN/A Current Ratio2.55 Quick Ratio2.55 Sales & Book Value Annual Sales$260,000.00 Price / Sales32.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.78 per share Price / Book0.65Miscellaneous Outstanding Shares7,220,000Free Float6,155,000Market Cap$8.38 million OptionableNot Optionable Beta1.32 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report Key ExecutivesDr. Milton H. Werner Ph.D. (Age 60)CEO, President & Director Comp: $697.96kDr. Roger RushHead of Preclinical ResearchDr. Surendra SinghHead of Chemistry, Manufacturing & ControlsDr. Charles Warren Olanow B.Sc.F.R.C.P.C., M.D., CEO of Clintrex Research Corporation & Member of Scientific Advisory BoardDan WilliamsControllerKey CompetitorsCyclo TherapeuticsNASDAQ:CYTHOKYO PharmaNASDAQ:OKYOAchilles TherapeuticsNASDAQ:ACHLSurrozenNASDAQ:SRZNQuince TherapeuticsNASDAQ:QNCXView All Competitors IKT Stock Analysis - Frequently Asked Questions How have IKT shares performed this year? Inhibikase Therapeutics' stock was trading at $1.27 at the beginning of the year. Since then, IKT stock has decreased by 8.7% and is now trading at $1.16. View the best growth stocks for 2024 here. How were Inhibikase Therapeutics' earnings last quarter? Inhibikase Therapeutics, Inc. (NYSE:IKT) released its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.06. When did Inhibikase Therapeutics' stock split? Inhibikase Therapeutics shares reverse split on Friday, June 30th 2023. The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split. When did Inhibikase Therapeutics IPO? Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO. How do I buy shares of Inhibikase Therapeutics? Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:IKT) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredNYSE biotech company's drug could be as revolutionary as penicillin!NV-387 could be a single drug to treat all of the "tripledemic" viruses and more! See how NV-387 could be h...Financial Markets Daily | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibikase Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibikase Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.